Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leading Study: Peginterferon alfa-2b Retreatment in Chronic Hepatitis B
NCT06323681Recruiting
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms). Primary endpoint: Proportion of patients with HBsAg below the lower limit of detection at 48 weeks. Started Feb 2024; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06323681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323681.